Effect of Oral Minocycline on Acute Stroke Outcome: A Randomized Open Label Prospective Study

2023-05-16-MMC

The goal of this study is to determine if oral Minocycline's proposed neuroprotective effects further improve the clinical outcomes, including mortality, of acute stroke patients beyond the current standard stroke care in a large scale randomized prospective open label (outcome assessor blinded) clinical trial. Participants will be randomly assigned (1:1) to take Minocycline 200mg orally every 24 hours for five days, starting within 24 hours from stroke symptoms onset, in addition to standard care or standard care alone. NIHSS (The National Institutes of Health Stroke Scale) and mRS (Modified Rankin Scale) will be collected at the time of presentation, discharge and again at 30- and 90-days post-discharge. All-cause mortality will also be obtained at 30 days and 90 days.

2023-11-01

2025-11-01

2026-02-01

Recruiting

Early phase I

1120

Inclusion Criteria: 1. Age \>/=18 2. Acute onset neurological deficit consistent with acute ischemic stroke or on imaging consistent with acute ischemia as defined by WHO (World Health Organization) guidelines 3. Acute onset of neurological deficits with intracerebral Hemorrhage on imaging consistent with intracerebral bleed 4. The onset of symptoms less than 24 hours 5. Measurable neurological deficit using NIHSS (National Institutes of Health Stroke Scale ) Exclusion Criteria: 1. Clinically not suspect stroke. 2. Allergic to the Tetracycline group of medications or Intolerance to Minocycline 3. Pregnancy or suspected pregnancy 4. Previous history of intolerance to minocycline 5. Acute or chronic renal failure 6. Any patients with contraindications to undergo CT/ MRI 7. Life expectancy less than one year or severe co-morbidities or comfort measure only (CMO) on admission 8. Pre-existing infectious disease requiring antibiotics 9. Inability to tolerate enteral medications/feeds 10. Patient/ family refusal

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Randomized, open label study', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'Outcome assessors will contact and obtain primary outcome measures of mRS without the knowledge of participants group assignment/treatment received.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 1120, 'type': 'ESTIMATED'}}

2023-11-18